01. Doctor Overview

Doctor Overview

Dr. Kradin has built an extensive career with knowledge and training in pulmonary medicine, anatomic pathology, basic immunology and psychiatry. One of his main areas of focus is the immunopathology of lung disease. Through his research, he has made significant contributions to the study of antigen processing by dendritic cells and the immunopathogenesis of acute interstitial lung injury and chronic interstitial lung injury.

Dr. Kradin as contributed to a variety of articles and texts, covering various topics. His work surrounding medicine and pathology has allowed him to develop an NIH-funded clinical trial that uses the adoptive transfer of autologous tumor-specific activated lymphocytes and interleukin-2 for the treatment of advanced cancers. This study in particular has been pioneered by Dr. Kradin in an effort to personalize cancer treatment with an approach that can be used for cancers like advanced malignant melanoma and renal cell carcinoma.

02. Fast Facts

Doctor Fast Facts

Main Speciality: Pathology

Other Interests & Specialties: Pulmonology, thoracic cancers, unexplained dyspnea, asbestosis, pulmonary pathophysiology, general internal medicine, anatomic pathology, basic immunology, psychiatry, chronic fatigue syndrome, interstitial lung disease, multiple chemical sensitivity and pulmonary immunology.

Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Pulmonary Disease, American Board of Internal Medicine Certification in Internal Medicine, American Board of Pathology Certification in Anatomic Pathology, American Board of Pathology Certification in Pathology, Gravida Award

Education & Experience:

• Medical Degree from Jefferson Medical College
• Residency in Anatomic and Clinical Pathology at Massachusetts General Hospital
• Residency in Internal Medicine at Pennsylvania Hospital
• Fellowship in Pulmonary Disease at Massachusetts General Hospital

03. Publications

Publications

Diffuse peritoneal mesothelioma: A case series of 62 patients including paraoccupational exposures to chrysotile asbestos. American Journal of Industrial Medicine. November 2017;60(11):963-967. doi: 10.1002/ajim.22768

Pathological recognition of diffuse malignant mesothelioma of the pleura: the significance of the historical perspective as regards this signal tumor. Seminars in Diagnostic Pathology. February 2006;23(1):25-34.

Distinguishing benign mesothelial hyperplasia from neoplasia: a practical approach. Seminars in Diagnostic Pathology. February 2006;23(1):4-14.